Re: Transfer of ZEN from RBC DI to TFSA
in response to
by
posted on
May 14, 2019 10:32AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Here is a question for the board, the current MV is .63cents USD and has been that way for now quite sometime and the latest Zenith PP was $2 USd and we have moved well into end of phase 2 with release of trial data coming up i assume,
Why then is the MV currently at .63uSd and not the $2usd that the PP have been the last one. This bodes well for those transfering to registered accounts and if there is a buyout then even better for shareholders....